vs
Side-by-side financial comparison of BridgeBio Pharma, Inc. (BBIO) and Purple Innovation, Inc. (PRPL). Click either name above to swap in a different company.
BridgeBio Pharma, Inc. is the larger business by last-quarter revenue ($154.2M vs $140.7M, roughly 1.1× Purple Innovation, Inc.). Purple Innovation, Inc. runs the higher net margin — -2.3% vs -126.2%, a 124.0% gap on every dollar of revenue. On growth, BridgeBio Pharma, Inc. posted the faster year-over-year revenue change (2521.2% vs 9.1%). Purple Innovation, Inc. produced more free cash flow last quarter ($-7.8M vs $-56.5M).
Brent Saunders is an American biopharma executive and entrepreneur who is the chairman and CEO of the health company Bausch & Lomb. He helped lead various mergers and acquisitions, including the mergers between Merck and Schering-Plough, the acquisition of Bausch + Lomb by Valeant Pharmaceuticals, and the $63 billion acquisition of Allergan by Abbvie. He founded the special-purpose acquisition company (SPAC) Vesper Healthcare Acquisition. Saunders is also executive chairman of medical aesthet...
Purple Carrot is a Needham, Massachusetts-based, and 100% plant-based meal kit company. Founded by Andy Levitt, it offers both prepared meals as well as meal kits to subscribers weekly. As stated in a 2022 article in Cosmopolitan, “each Purple Carrot meal kit results in 72% less carbon being released into the atmosphere as compared to the standard American meal.”
BBIO vs PRPL — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $154.2M | $140.7M |
| Net Profit | $-194.6M | $-3.2M |
| Gross Margin | 94.7% | 41.9% |
| Operating Margin | -90.5% | -1.6% |
| Net Margin | -126.2% | -2.3% |
| Revenue YoY | 2521.2% | 9.1% |
| Net Profit YoY | 27.2% | 62.1% |
| EPS (diluted) | $-1.00 | $0.03 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $154.2M | $140.7M | ||
| Q3 25 | $120.7M | $118.8M | ||
| Q2 25 | $110.6M | $105.1M | ||
| Q1 25 | $116.6M | $104.2M | ||
| Q4 24 | — | $129.0M | ||
| Q3 24 | — | $118.6M | ||
| Q2 24 | — | $120.3M | ||
| Q1 24 | $211.1M | $120.0M |
| Q4 25 | $-194.6M | $-3.2M | ||
| Q3 25 | $-184.9M | $-11.7M | ||
| Q2 25 | $-183.8M | $-17.3M | ||
| Q1 25 | $-169.6M | $-19.1M | ||
| Q4 24 | — | $-8.5M | ||
| Q3 24 | — | $-39.2M | ||
| Q2 24 | — | $27.0K | ||
| Q1 24 | $-36.2M | $-50.2M |
| Q4 25 | 94.7% | 41.9% | ||
| Q3 25 | 94.6% | 42.8% | ||
| Q2 25 | 96.7% | 35.9% | ||
| Q1 25 | 97.7% | 39.4% | ||
| Q4 24 | — | 42.9% | ||
| Q3 24 | — | 29.7% | ||
| Q2 24 | — | 40.7% | ||
| Q1 24 | 99.7% | 34.8% |
| Q4 25 | -90.5% | -1.6% | ||
| Q3 25 | -120.3% | -10.2% | ||
| Q2 25 | -121.4% | -13.5% | ||
| Q1 25 | -89.5% | -13.9% | ||
| Q4 24 | — | -6.0% | ||
| Q3 24 | — | -39.5% | ||
| Q2 24 | — | -12.1% | ||
| Q1 24 | 0.2% | -19.3% |
| Q4 25 | -126.2% | -2.3% | ||
| Q3 25 | -153.2% | -9.9% | ||
| Q2 25 | -166.2% | -16.5% | ||
| Q1 25 | -145.4% | -18.4% | ||
| Q4 24 | — | -6.6% | ||
| Q3 24 | — | -33.1% | ||
| Q2 24 | — | 0.0% | ||
| Q1 24 | -17.1% | -41.8% |
| Q4 25 | $-1.00 | $0.03 | ||
| Q3 25 | $-0.95 | $0.11 | ||
| Q2 25 | $-0.95 | $0.16 | ||
| Q1 25 | $-0.88 | $0.18 | ||
| Q4 24 | — | $0.08 | ||
| Q3 24 | — | $0.36 | ||
| Q2 24 | — | $0.00 | ||
| Q1 24 | $-0.20 | $0.47 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $570.1M | $24.3M |
| Total DebtLower is stronger | $2.0B | $126.7M |
| Stockholders' EquityBook value | $-2.1B | $-29.7M |
| Total Assets | $936.0M | $296.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $570.1M | $24.3M | ||
| Q3 25 | $643.0M | $32.4M | ||
| Q2 25 | $756.9M | $34.2M | ||
| Q1 25 | $540.6M | $21.6M | ||
| Q4 24 | — | $29.0M | ||
| Q3 24 | — | $23.4M | ||
| Q2 24 | — | $23.4M | ||
| Q1 24 | $519.7M | $34.5M |
| Q4 25 | $2.0B | $126.7M | ||
| Q3 25 | $2.0B | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $70.7M | ||
| Q3 24 | — | $50.8M | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $-2.1B | $-29.7M | ||
| Q3 25 | $-1.9B | $-26.9M | ||
| Q2 25 | $-1.8B | $-15.6M | ||
| Q1 25 | $-1.6B | $1.3M | ||
| Q4 24 | — | $20.2M | ||
| Q3 24 | — | $28.0M | ||
| Q2 24 | — | $66.4M | ||
| Q1 24 | $-1.0B | $65.5M |
| Q4 25 | $936.0M | $296.3M | ||
| Q3 25 | $998.3M | $302.1M | ||
| Q2 25 | $1.1B | $303.8M | ||
| Q1 25 | $881.6M | $293.8M | ||
| Q4 24 | — | $307.8M | ||
| Q3 24 | — | $309.3M | ||
| Q2 24 | — | $362.1M | ||
| Q1 24 | $849.3M | $382.1M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 3.50× | ||
| Q3 24 | — | 1.82× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-56.4M | $-5.8M |
| Free Cash FlowOCF − Capex | $-56.5M | $-7.8M |
| FCF MarginFCF / Revenue | -36.6% | -5.5% |
| Capex IntensityCapex / Revenue | 0.0% | 1.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-41.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-56.4M | $-5.8M | ||
| Q3 25 | $-109.6M | $-968.0K | ||
| Q2 25 | $-80.7M | $-4.0M | ||
| Q1 25 | $-199.2M | $-23.1M | ||
| Q4 24 | — | $6.8M | ||
| Q3 24 | — | $1.1M | ||
| Q2 24 | — | $-8.9M | ||
| Q1 24 | $-219.5M | $-16.8M |
| Q4 25 | $-56.5M | $-7.8M | ||
| Q3 25 | $-110.0M | $-1.8M | ||
| Q2 25 | $-81.3M | $-7.0M | ||
| Q1 25 | — | $-25.3M | ||
| Q4 24 | — | $5.7M | ||
| Q3 24 | — | $101.0K | ||
| Q2 24 | — | $-11.0M | ||
| Q1 24 | $-220.2M | $-19.9M |
| Q4 25 | -36.6% | -5.5% | ||
| Q3 25 | -91.2% | -1.5% | ||
| Q2 25 | -73.5% | -6.6% | ||
| Q1 25 | — | -24.3% | ||
| Q4 24 | — | 4.4% | ||
| Q3 24 | — | 0.1% | ||
| Q2 24 | — | -9.2% | ||
| Q1 24 | -104.3% | -16.5% |
| Q4 25 | 0.0% | 1.4% | ||
| Q3 25 | 0.4% | 0.7% | ||
| Q2 25 | 0.5% | 2.8% | ||
| Q1 25 | 0.0% | 2.2% | ||
| Q4 24 | — | 0.8% | ||
| Q3 24 | — | 0.9% | ||
| Q2 24 | — | 1.7% | ||
| Q1 24 | 0.3% | 2.5% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -330.22× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BBIO
Segment breakdown not available.
PRPL
| Cost Of Revenues | $81.7M | 58% |
| Other | $59.0M | 42% |
